

Daniel B Schmolze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5720554/publications.pdf>

Version: 2024-02-01

46
papers

1,143
citations

394421

19
h-index

414414

32
g-index

48
all docs

48
docs citations

48
times ranked

2091
citing authors

#	ARTICLE	IF	CITATIONS
1	Stressed out and fed up: The effect of stress on maternal feeding behaviors and the moderating role of executive function. <i>Appetite</i> , 2022, 168, 105762.	3.7	1
2	MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 603-612.e7.	0.7	9
3	Molecular Imaging of HER2 in Patient Tissues with Touch Prep-Quantitative Single Molecule Localization Microscopy. <i>Methods in Molecular Biology</i> , 2022, 2394, 231-248.	0.9	1
4	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-“positive breast cancer. <i>JCI Insight</i> , 2022, 7, .	5.0	17
5	Hyperthermic Intraperitoneal Chemotherapy-“Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100239.	3.0	10
6	Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 2795.	3.7	7
7	Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1079-1079.	1.6	0
8	Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 3159.	3.7	5
9	Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, e382-e393.	3.7	27
10	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2021, 26, 99-e217.	3.7	49
11	Physics approaches to the spatial distribution of immune cells in tumors. <i>Reports on Progress in Physics</i> , 2021, 84, 022601.	20.1	10
12	Raman spectroscopy and artificial intelligence to predict the Bayesian probability of breast cancer. <i>Scientific Reports</i> , 2021, 11, 6482.	3.3	23
13	Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. , 2021, 9, e002084.		16
14	Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. <i>Npj Breast Cancer</i> , 2021, 7, 84.	5.2	16
15	Phase I/II trial of palbociclib, pembrolizumab-“and letrozole in patients with hormone receptor-positive metastatic breast cancer. <i>European Journal of Cancer</i> , 2021, 154, 11-20.	2.8	34
16	Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. <i>European Journal of Radiology</i> , 2021, 144, 109948.	2.6	6
17	Quantitative Impact of the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Practice Guideline Update on Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: A Systematic Analysis. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 887-890.	2.5	4
18	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. <i>Clinical Cancer Research</i> , 2020, 26, 657-668.	7.0	70

#	ARTICLE	IF	CITATIONS
19	Accuracy of gross intraoperative margin assessment for breast cancer: experience since the SSO-ASTRO margin consensus guidelines. <i>Scientific Reports</i> , 2020, 10, 17344.	3.3	26
20	Towards integration of ⁶⁴ Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2+ breast cancer. <i>Scientific Reports</i> , 2020, 10, 20518.	3.3	28
21	Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis. <i>PLoS ONE</i> , 2020, 15, e0229955.	2.5	20
22	Occupancy and Fractal Dimension Analyses of the Spatial Distribution of Cytotoxic (CD8+) T Cells Infiltrating the Tumor Microenvironment in Triple Negative Breast Cancer. <i>Biophysical Reviews and Letters</i> , 2020, 15, 83-98.	0.8	3
23	Clinical vs genomic risks in breast cancer in 2019: Breast pathologist's appellate review of the controversial results from TAILORx trial. <i>Breast Journal</i> , 2020, 26, 1447-1448.	1.0	0
24	Leiomyoadenomatoid Tumor of Epididymis: A Variant of Adenomatoid Tumor. <i>Annals of Clinical and Laboratory Science</i> , 2020, 50, 813-817.	0.2	2
25	Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. <i>Clinical Cancer Research</i> , 2019, 25, 544-551.	7.0	34
26	Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. <i>Nature Immunology</i> , 2019, 20, 1220-1230.	14.5	117
27	Raman Spectroscopy for Rapid Evaluation of Surgical Margins during Breast Cancer Lumpectomy. <i>Scientific Reports</i> , 2019, 9, 14639.	3.3	61
28	Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. <i>PLoS ONE</i> , 2019, 14, e0224726.	2.5	29
29	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	5.0	21
30	Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes. <i>BMC Cancer</i> , 2019, 19, 881.	2.6	19
31	Distribution of Cholesterol and HER2 in Patient Breast Cancer Cells using Quantitative Single Molecule Localization Microscopy. <i>Biophysical Journal</i> , 2019, 116, 440a.	0.5	0
32	An Automatable Method for Determining Adequacy of Thyroid Fine-Needle Aspiration Samples. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 1084-1088.	2.5	1
33	Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. <i>Clinical Cancer Research</i> , 2018, 24, 395-406.	7.0	18
34	[Regular Paper] MVPNets: Multi-viewing Path Deep Learning Neural Networks for Magnification Invariant Diagnosis in Breast Cancer. , 2018, , .		9
35	Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2. <i>Scientific Reports</i> , 2018, 8, 15154.	3.3	28
36	Crowdsourcing scoring of immunohistochemistry images: Evaluating Performance of the Crowd and an Automated Computational Method. <i>Scientific Reports</i> , 2017, 7, 43286.	3.3	31

#	ARTICLE	IF	CITATIONS
37	Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. <i>Oncolimmunology</i> , 2017, 6, e1363138.	4.6	20
38	Direct comparison between confocal and multiphoton microscopy for rapid histopathological evaluation of unfixed human breast tissue. <i>Journal of Biomedical Optics</i> , 2016, 21, 126021.	2.6	34
39	Using Point of Care Glucose Meters in the Critically Ill. <i>Point of Care</i> , 2016, 15, 137-143.	0.4	4
40	A 63-Year-Old Man With Rapidly Progressive Dementia. <i>Clinical Infectious Diseases</i> , 2016, 63, 138-139.	5.8	4
41	EMDomics: a robust and powerful method for the identification of genes differentially expressed between heterogeneous classes. <i>Bioinformatics</i> , 2016, 32, 533-541.	4.1	60
42	Abstract 2172: Earth mover's distance for the identification of genes associated with drug resistance in cancer., 2015,, .		0
43	Assessment of breast pathologies using nonlinear microscopy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15304-15309.	7.1	169
44	Characterization and Analysis of the Composition and Dynamics of the Mammalian Riboproteome. <i>Cell Reports</i> , 2013, 4, 1276-1287.	6.4	50
45	Value of Additional Level Sections in the Evaluation of Lymph Nodes for Endometrial Carcinoma Staging. <i>American Journal of Clinical Pathology</i> , 2013, 140, 516-518.	0.7	7
46	Advances in Microscopy Techniques. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 255-263.	2.5	41